In Vitro Bioavailability Study of an Antiviral Compound Enisamium Iodide.

Area of Science:

• Biopharmaceutics
• Drug Discovery
• Pharmacokinetics

Background:

• Enisamium iodide is an antiviral compound.
• Understanding its biopharmaceutic properties is crucial for predicting in vivo performance.

Purpose of the Study:

• To classify enisamium iodide according to the Biopharmaceutics Classification System (BCS).
• To evaluate the in vitro bioavailability, specifically solubility and permeability, of enisamium iodide.

Main Methods:

• Solubility was measured in four buffer solutions across a pH range of 1.2 to 7.5 at 25 °C and 37 °C.
• Apparent intestinal permeability (Papp) was assessed using Caco-2 cell monolayers at concentrations of 10–100 μM.

Main Results:

• Enisamium iodide demonstrated high solubility, with values ranging from 60 mg/mL at 25 °C to 130–150 mg/mL at 37 °C.
• Low apparent intestinal permeability was observed, with permeability coefficients between 0.2 × 10⁻⁶ cm s⁻¹ and 0.3 × 10⁻⁶ cm s⁻¹.
• Based on high solubility and low permeability, enisamium iodide was classified as BCS Class III.

Conclusions:

• Enisamium iodide is a highly soluble compound with low permeability.
• The compound fits into Class III of the Biopharmaceutics Classification System.
• Further in vivo animal and human studies are required to confirm the bioavailability of enisamium iodide.